This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment.

Registry ID

EUCTR2012-001306-20

Source registry

EUCTR

Phase

PHASE1

Sponsor

The National Cancer Institute (NCI)

Last update

2026-08-16

Conditions

• Refractory solid tumors

Summary

1. To estimate the maximum tolerated dose (MTD) and/or recommended Phase II dose of oral pazopanib administered on a once daily schedule to children with refractory solid tumors. 2. To define and describe the toxicities of oral pazopanib administered as either a tablet or suspension. 3. To characterize the pharmacokinetics of oral pazopanib in children with refractory solid tumors.

View on source registry